APUS · Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. has disclosed a significant regulatory compliance issue with NYSE American, triggered by its failure to file the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, by the prescribed deadline. The notice, received on April 17, 2026, formally places the company out of compliance with Section 1007 of the NYSE American Company Guide, which governs timely filing requirements. This initiates a formal remediation process. The company has been granted an initial cure period of six months, ending October 15, 2026, during which it must file the delinquent report to avoid further regulatory action. While the company's stock remains listed, it now bears the '.LF' designation, a public marker of its non-compliance status that may affect investor perception and trading. Importantly, a separate trading halt initiated on April 2, 2026, remains in effect, indicating pre-existing trading restrictions unrelated to this filing delay. The company attributes the delay to the ongoing preparation and finalization of its financial statements and the additional time required by its independent auditor to complete audit procedures. Management has stated an expectation to file by April 30, 2026, but explicitly cautions that this timeline is not guaranteed. The NYSE American retains broad discretion in this process; it may grant an additional six-month cure period, truncate the cure periods, or commence suspension and delisting procedures if it deems continued listing inadvisable. The company is required to engage with NYSE American officials within five days of receiving the notice. This event represents a material risk to continued listing, a foundational requirement for maintaining access to public equity markets and investor confidence.